Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Surface Membrane Barriers

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...

Desmosomes

Desmosomes

The term desmosome derives from the Greek words "desmo" and "soma" meaning "adhesion bodies." This structure was first observed during the late 1800s and described as small, dense nodules in the epidermis. Desmosomes are button-like structures that help form an interlinked network of intermediate filaments across the cells. These junctions are essential to hold cells together under mechanical stress and to maintain tissue integrity. Desmosomes are multi-protein complexes comprising desmosomal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

French national protocol for diagnosis and management of pemphigoid gestationis.

Annales de dermatologie et de venereologie·2026

Same author

Prevalence of sleep disorders in patients with bullous pemphigoid.

Annales de dermatologie et de venereologie·2026

Same author

Evolution of rituximab use over time in moderate-to-severe pemphigus: A two-centre retrospective study.

Annales de dermatologie et de venereologie·2024

Same author

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same author

Observational study of a series of basal cell carcinomas: Evaluation of location as a risk factor for recurrence.

Journal of stomatology, oral and maxillofacial surgery·2022

Same author

Updated French guidelines for the therapeutic management of bullous pemphigoid.

Annales de dermatologie et de venereologie·2021

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

[Mucous membrane pemphigoid: a review].

C Bédane¹, V Doffoel Hantz

¹Service de dermatologie, hôpital Dupuytren, 2 avenue Martin-Luther-King, Limoges cedex, France. christophe.bedane@chu-limoges.fr

Annales De Dermatologie Et De Venereologie

|March 15, 2011

Summary

This summary is machine-generated.

Mucous membrane pemphigoid (MMP) treatment lacks strong evidence due to few trials. Dapsone is the primary treatment for non-ocular MMP, with other options available for intolerance or ineffectiveness.

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Jun 3, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Area of Science:

Dermatology
Autoimmune diseases
Ophthalmology

Background:

Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease.
Limited treatment options are available for MMP, necessitating a review of proposed regimens.

Purpose of the Study:

To systematically review the literature on the efficacy and tolerance of proposed treatment regimens for mucous membrane pemphigoid (MMP).

Main Methods:

Systematic literature review of randomized controlled trials (RCTs) and uncontrolled studies.
Searched PubMed and Embase databases up to April 2009.
Analyzed 24 series, primarily retrospective or case reports, due to the scarcity of clinical trials.

Main Results:

Evidence for MMP treatments is generally weak, with a lack of prospective comparative studies.
Dapsone is the recommended first-line treatment for non-ocular MMP.
For ocular MMP, treatment targets severity and chronicity, with dapsone for non-scarring conjunctivitis and corticosteroids or cyclophosphamide for flares. Immunomodulating drugs are under evaluation for refractory cases.

Conclusions:

The optimal therapeutic regimen for MMP cannot be definitively identified due to insufficient high-quality comparative studies.
Dapsone remains the initial treatment of choice for MMP.
Immunosuppressive or immunomodulating therapies require individualized patient consideration.